Prana Biotech crash pinches rich listers
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
More than three quarters of the value in Prana Biotechnology (PBT) stock has disintegrated this morning after the dual-listed company announced its phase 2b trial failed to reduce the symptoms of Alzheimer’s disease.
Shares in the once-loved biotech have plunged 77% to 24 cents at 1100 AEDT – following a similar response in the US overnight – in response to the news.
Some of Australia’s wealthiest families have been caught up in the share price plunge with both the Smorgon and Lieberman families well-known stakeholders in the company.
Prana said that its drug PBT2 did not reach its primary endpoint to show a statistically significant reduction in the levels of beta-amyloid plaques in the brains of Alzheimer’s disease patients. Though the treatment did show an overall reduction, the company said there was also an “atypical reduction” from the placebo patients as well.
“Whilst not meeting our hopes, the result does not deter us from the future development of PBT2,” chief executive Geoffrey Kempler said.
The shocking share price reaction will hit a number of ‘rich list’ familes:The Smorgon family, worth about $2.64 billion, hold around one million shares in Prana, while the Liberman family (worth $2.1 billion) owns a private company that holds a 3.72% stake.
Prior to today, Prana had been one of the exceptional biotech stories: the stock had soared around 460% in the past year.
Call 1300 880 160
Start a chat
Schedule a call
